Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-12-22 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Four Lots of Quinapril Tablets due to potential presence of N-Nitroso-Quinapril Impurity.
Regulatory Filings Classification · 95% confidence The document is a press release dated December 22, 2022, from Lupin Limited, disclosing a voluntary nationwide recall of Quinapril Tablets due to the presence of a nitrosamine impurity. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure obligations. The content focuses on the recall details, distribution, and contact information for affected parties. There are no financial statements, management discussion, or regulatory certifications present. The document is a regulatory disclosure announcement about a product recall, not a financial report or management update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-22 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated December 22, 2022, from Lupin Limited addressed to stock exchanges in India. It discloses a voluntary nationwide recall of Quinapril Tablets due to the presence of a nitrosamine impurity. The content focuses on the recall details, affected product lots, distribution, and consumer guidance. There is no financial data, management discussion, or regulatory filing typical of financial reports. The document is a regulatory disclosure pursuant to SEBI Listing Regulations, specifically a voluntary product recall announcement. It does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a legal proceeding update or a capital/financing update. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories. The document length (7605 characters) and content confirm it is a full disclosure, not just a brief announcement or certification. Confidence is high due to clear regulatory disclosure nature and absence of financial or governance content.
2022-12-22 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new Regional Reference Laboratory by Lupin Diagnostics in Indore, Madhya Pradesh. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to material events or information. The content focuses on business expansion and operational updates rather than financial results, management changes, or regulatory filings. It does not contain financial statements or detailed financial analysis, nor does it announce voting results, dividends, or capital changes. The document is a corporate announcement about business expansion, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and disclosure that does not fit other specific categories.
2022-12-21 English
Lupin Diagnostics Expands its Footprint in Central India; Launches Regional Reference Laboratory in Indore.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new Regional Reference Laboratory by Lupin Diagnostics in Indore, Madhya Pradesh. It is addressed to stock exchanges (BSE and NSE) and references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content focuses on business expansion and operational updates rather than financial results, management changes, or regulatory filings. The document is not a financial report, earnings release, management discussion, or any form of regulatory filing. It is a corporate announcement about a business development event. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2022-12-21 English
Lupin Receives Approval from U.S. FDA for Brivaracetam Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for Lupin Limited's Abbreviated New Drug Application for Brivaracetam Tablets. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations. The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is 4128 characters, which is relatively short and consistent with a press release or regulatory announcement. There is no financial data, no discussion of financial results, no voting results, no management changes, or other report types. Therefore, the document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and disclosures that do not fit other categories.
2022-12-21 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for Lupin Limited's Abbreviated New Drug Application for Brivaracetam Tablets. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations. The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is 4113 characters, which is relatively short and consistent with a press release or regulatory announcement. There is no financial data, no discussion of financial results, no meeting materials, no voting results, no legal proceedings, no capital changes, and no insider transactions. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and disclosure under listing obligations that does not fit into other specific categories.
2022-12-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.